Invitae Corp (Invitae) is a medical genetics company that provides testing, health data and digital health solutions for various genetic disorders. The company provides genetic testing services in multiple clinical areas that include hereditary cancer, women's health, precision oncology, pharmacogenomics and rare diseases. It uses process automation, proprietary design, robotics and bioinformatics software solutions to support genetic counseling, variant interpretation, and clinical trial matching. The company serves payers, healthcare providers, biopharma partners and patient advocacy groups. It operates in Australia, India, Japan, Singapore, Belgium, Germany, Latvia, the Netherlands, the US, Israel and Brazil. Invitae is headquartered in San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company InVitae Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- InVitae Corp Company Overview
- InVitae Corp Company Snapshot
- InVitae Corp Pipeline Products and Ongoing Clinical Trials Overview
- InVitae Corp - Pipeline Analysis Overview
- InVitae Corp - Key Facts
- InVitae Corp - Major Products and Services
- InVitae Corp Pipeline Products by Development Stage
- InVitae Corp Pipeline Products Overview
- Comprehensive Cancer Array Test
- Comprehensive Cancer Array Test Product Overview
- Diagnostic Test - Pre-Pregnancy
- Diagnostic Test - Pre-Pregnancy Product Overview
- Expanded Carrier Screening Test
- Expanded Carrier Screening Test Product Overview
- Genomic Panel
- Genomic Panel Product Overview
- Molecular Assay - Age-Related Macular Degeneration
- Molecular Assay - Age-Related Macular Degeneration Product Overview
- NTRK CDx
- NTRK CDx Product Overview
- Personalized Cancer Monitoring Laboratory Developed Test
- Personalized Cancer Monitoring Laboratory Developed Test Product Overview
- Therapy selection LDT
- Therapy selection LDT Product Overview
- InVitae Corp - Key Competitors
- InVitae Corp - Key Employees
- InVitae Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- InVitae Corp, Recent Developments
- Mar 05, 2024: Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
- Nov 06, 2023: Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
- Oct 25, 2023: Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
- Oct 19, 2023: Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
- Oct 16, 2023: InVitae Receives DeNovo Clearance for Invitae Common Hereditary Cancers Panel
- Oct 12, 2023: Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
- Sep 29, 2023: FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
- Sep 25, 2023: Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
- Aug 28, 2023: Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
- Aug 15, 2023: Clinical Trial Results Support Genetic Testing Of All Patients With Prostate Cancer
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- InVitae Corp Pipeline Products and Ongoing Clinical Trials Overview
- InVitae Corp Pipeline Products by Equipment Type
- InVitae Corp Pipeline Products by Indication
- InVitae Corp, Key Facts
- InVitae Corp, Major Products and Services
- InVitae Corp Number of Pipeline Products by Development Stage
- InVitae Corp Pipeline Products Summary by Development Stage
- Comprehensive Cancer Array Test - Product Status
- Comprehensive Cancer Array Test - Product Description
- Diagnostic Test - Pre-Pregnancy - Product Status
- Diagnostic Test - Pre-Pregnancy - Product Description
- Expanded Carrier Screening Test - Product Status
- Expanded Carrier Screening Test - Product Description
- Genomic Panel - Product Status
- Genomic Panel - Product Description
- Molecular Assay - Age-Related Macular Degeneration - Product Status
- Molecular Assay - Age-Related Macular Degeneration - Product Description
- NTRK CDx - Product Status
- NTRK CDx - Product Description
- Personalized Cancer Monitoring Laboratory Developed Test - Product Status
- Personalized Cancer Monitoring Laboratory Developed Test - Product Description
- Therapy selection LDT - Product Status
- Therapy selection LDT - Product Description
- InVitae Corp, Key Employees
- InVitae Corp, Subsidiaries
- Glossary
- InVitae Corp Pipeline Products by Equipment Type
- InVitae Corp Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Revvity Inc
- NeoGenomics Inc
- Natera Inc
- Tempus Labs Inc
- Foundation Medicine Inc
- Athena Diagnostics Inc
- GeneDx Holdings Corp
- Emory Genetics Laboratory
- Medical Neurogenetics LLC
- Connective Tissue Gene Tests
- Correlagen Diagnostics Inc
- Sequenom Inc
- Guardant Health Inc
- Exact Sciences Corp
- CooperSurgical Inc
- PreventionGenetics LLC
- Myriad Genetics Inc
- Integrated Genetics
- Centogene NV
- Caris Life Sciences Inc
- Ambry Genetics Corp
- Fulgent Genetics Inc
- Blueprint Genetics Inc
- Baylor Miraca Genetics Laboratories
